Skip to content

Thalidomide, Clarithromycin and Dexamethasone Regimen for Patients With Newly Diagnosed Multiple Myeloma

Thalidomide, Clarithromycin and Dexamethasone Regimen for Patients With Newly Diagnosed Multiple Myeloma: a multicenter, open-label study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014946
Enrollment
Unknown
Registered
2018-02-24
Start date
2018-03-01
Completion date
Unknown
Last updated
2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

Case series:Thalidomide, Clarithromycin and Dexamethasone

Sponsors

Bejing Chaoyang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years old, not available or acceptable for transplantation; 2. Expected survival more than 6 months; 3. Newly diagnosed symptomatic multiple myeloma (stage IB, II and III); 4. Signed informed consent form; 5. Contraception methods are needed for females in child bearing period and males.

Exclusion criteria

Exclusion criteria: 1. Karnofsky performance status lower than 60; 2. Serum AST or ALT more than triple of the upper limit; serum total bilirubin more than double of the upper limit; 3. Serum platelet count lower than 50×10^9/L; 4. Serum hemoglobin lower than 60g/L; 5. Serum neutrophils count lower than 0.75×10^9/L; 6. Creatinine clearance rate lower than 30ml/min; 7. Grade 2 or higher peripheral neuropathy; 8. Plan for hematopoietic stem cell transplantation within 18 months; 9. Received plasmapheresis within one week before enrolling; 10. Hypersensitivity to thalidomide, clarithromycin or any of its excipients, erythromycin, or any of the macrolide antibiotics; 11. A history of severe or uncontrolled cardiovascular disease, including myocardial infarction, grade II to IV cardiac insufficiency, uncontrolled angina, pericardial disease or cardiac amyloidosis; 12. Females in pregnancy or lactation; 13. Unwilling or unable to take contraception methods (for females in child bearing period and males); 14. Any condition which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

Design outcomes

Primary

MeasureTime frame
Percentage of participants with very good partial remission (VGPR) or better;

Secondary

MeasureTime frame
Percentage of paticipants with MRD negative;Overall response rate;Progression free survival;Overall survival;Quality of life;Toxicity;

Countries

China

Contacts

Public ContactWen Gao

Bejing Chaoyang Hospital

gaowenpingping@163.com+86 010-85231572

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026